Details of the Drug Combination

General Information of Drug Combination (ID: DCXKBEB)

Drug Combination Name
Azelaic Acid Brimonidine
Indication
Disease Entry Status REF
Acne Rosacea Phase 4 [1]
Component Drugs Azelaic Acid   DMHVL0J Brimonidine   DMQLT4N
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Azelaic Acid
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Approved [2]
Azelaic Acid Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) TT2A0DR S5A1_HUMAN; S5A2_HUMAN; PORED_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Azelaic Acid Interacts with 6 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Decreases Expression [6]
Tissue-type plasminogen activator (PLAT) OTQPDNAB TPA_HUMAN Decreases Expression [6]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Increases Expression [6]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Increases Expression [7]
Guanine nucleotide-binding protein G(olf) subunit alpha (GNAL) OTESDTEU GNAL_HUMAN Increases Response To Substance [8]
Guanine nucleotide-binding protein subunit alpha-15 (GNA15) OTFYRZGV GNA15_HUMAN Increases Response To Substance [8]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DOT(s)
Indication(s) of Brimonidine
Disease Entry ICD 11 Status REF
Ocular hypertension 9C61.01 Approved [3]
Glaucoma/ocular hypertension 9C61 Phase 3 [4]
Brimonidine Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adrenergic receptor alpha-2C (ADRA2C) TT2NUT5 ADA2C_HUMAN Modulator [3]
Adrenergic receptor Alpha-2 (ADRA2) TTQ8AFT NOUNIPROTAC Agonist [9]
------------------------------------------------------------------------------------
Brimonidine Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Alpha-2A adrenergic receptor (ADRA2A) OTZFGOTP ADA2A_HUMAN Increases ADR [10]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02147691) Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7484).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988 Nov;119(5):627-32.
6 Azelaic acid decreases the fibrinolytic potential of cultured human melanoma cells in vitro. Cancer Lett. 1996 Jun 5;103(2):125-9. doi: 10.1016/0304-3835(96)04185-7.
7 Azelaic acid modulates the inflammatory response in normal human keratinocytes through PPARgamma activation. Exp Dermatol. 2010 Sep;19(9):813-20. doi: 10.1111/j.1600-0625.2010.01107.x. Epub 2010 Jul 2.
8 Identification of specific ligands for orphan olfactory receptors. G protein-dependent agonism and antagonism of odorants. J Biol Chem. 2005 Mar 25;280(12):11807-15. doi: 10.1074/jbc.M411508200. Epub 2004 Dec 14.
9 Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum. 2000 Aug;43(8):1886-90.
10 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.